Standard BioTools to Divest Microfluidics Business to ARCHIMED

Key Facts

1Standard BioTools announced a definitive agreement to sell its Microfluidics business to healthcare investment firm ARCHIMED.

Standard BioTools announced a definitive agreement to sell its Microfluidics business unit to healthcare investment firm ARCHIMED. GlobeNewswire reported that the divestiture is part of a strategic move to streamline the company's portfolio, following a previous agreement to sell its Mass Cytometry unit.

LAB closed at $0.7447 on October 2, 2026, with a session high of $0.76 and a low of $0.7283. The transaction is expected to improve balance sheet liquidity and allow the company to refocus its strategic resources on core operations.